English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 4/5 criteria met. Data as of 04/11/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ✅ Debt passed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 15.00%
Price change 2019 → 2020: 6.31%
Price change 2020 → 2021: 44.36%
Price change 2021 → 2022: 4.11%
Price change 2022 → 2026: 0.00%
Financial growth
Revenue CAGR (8 years): 9.94%
Earnings CAGR (8 years): 9.65%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.03
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 18.99
P/E < 25.0 (maximum threshold).
Correction (6 months)
Price history over 6 months not available.
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ANTM" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Elevance Health Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 122 bn | 4.6 bn | 3.8 % | n/a |
| 2021 | 139 bn | 6.1 bn | 4.4 % | +13.8 % |
| 2022 | 157 bn | 5.9 bn | 3.8 % | +13.0 % |
| 2023 | 171 bn | 6.0 bn | 3.5 % | +9.4 % |
| 2024 | 177 bn | 6.0 bn | 3.4 % | +3.2 % |
| 2025 | 199 bn | 5.7 bn | 2.8 % | +12.6 % |
Amounts converted to USD. Source: published annual accounts, collected on 09/11/2026.
Valuation and competitors
Elevance Health Inc. compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering Elevance Health Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Analyst forecasts
| Fiscal year | Revenue | Net income | Expected EPS (range) | P/E on this EPS | Analysts |
|---|---|---|---|---|---|
| 2026 | 200 bn | 6.4 bn | 29.05 (27.69 / 30.17) | n/a | 12 |
| 2027 | 205 bn | 6.7 bn | 30.25 (29.35 / 31.33) | n/a | 12 |
| 2028 | 213 bn | 7.8 bn | 34.62 (32.70 / 37.22) | n/a | 5 |
Amounts in USD, the reporting currency.
Track record against expectations: reported EPS above consensus 10 times over the last 12 releases.
Rating changes (12 months)
| Date | Firm | Before | After |
|---|---|---|---|
| 27/10/2026 | Wells Fargo | Overweight | Overweight |
| 23/10/2026 | TD Cowen | Buy | Buy |
| 22/10/2026 | RBC Capital | Sector Perform | Sector Perform |
| 22/10/2026 | Barclays | Overweight | Overweight |
| 22/10/2026 | Guggenheim | Buy | Buy |
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee. Company data collected from its ELV listing (same ISIN).
Dividends and earnings
Elevance Health Inc.: dividend history, last distributions, stock splits and earnings releases.
Annual dividend per share (), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.
Latest ex-dividend dates
| Ex-dividend | Amount | Payment |
|---|---|---|
| 10/09/2026 | 1.72 | 25/09/2026 |
| 10/06/2026 | 1.72 | 25/06/2026 |
| 10/03/2026 | 1.72 | 25/03/2026 |
| 05/12/2025 | 1.71 | 19/12/2025 |
| 10/09/2025 | 1.71 | 25/09/2025 |
| 10/06/2025 | 1.71 | 25/06/2025 |
| 10/03/2025 | 1.71 | 25/03/2025 |
| 05/12/2024 | 1.63 | 20/12/2024 |
Stock splits
| Date | Operation |
|---|---|
| 01/06/2005 | split: 2 shares for 1 |
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Elevance Health Inc.
What is the revenue of Elevance Health Inc.?
199 bn USD for fiscal year 2025, with net income of 5.7 bn USD (net margin 2.8 %).
Does Elevance Health Inc. pay a dividend?
Yes. Latest dividend: 1.72 per share, ex-dividend on 10/09/2026. Over 12 months: 6.87.
When does Elevance Health Inc. report its next earnings?
The next release is expected on 27/01/2027. EPS expected by analysts: 2.08.
What do analysts say about Elevance Health Inc.?
Out of 38 analysts: 27 buy or strong buy, 11 hold, 0 sell or strong sell.
What is the P/E ratio of Elevance Health Inc.?
Trailing 12-month P/E of 14.5, against 26.8 for the sector median on the same exchange (10-year median: 22.3).
Is Elevance Health Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0367521038).
How many employees does Elevance Health Inc. have?
98,200 full-time employees according to the latest published profile.
Who runs Elevance Health Inc.?
Gail Boudreaux is the company's chief executive.